Aquestive Therapeutics (AQST) Stock Overview
Operates as a pharmaceutical company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AQST Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Aquestive Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.08 |
| 52 Week High | US$7.51 |
| 52 Week Low | US$2.12 |
| Beta | 1.76 |
| 1 Month Change | 46.58% |
| 3 Month Change | 68.57% |
| 1 Year Change | 40.76% |
| 3 Year Change | 686.75% |
| 5 Year Change | 34.60% |
| Change since IPO | -55.89% |
Recent News & Updates
Aquestive Therapeutics: A Measured Bet
Oct 12Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Sep 05
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
Aug 14Recent updates
Aquestive Therapeutics: A Measured Bet
Oct 12Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Sep 05Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
Aug 14After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar
Jul 21Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results
May 16
FDA Approval And Anaphylm Launch Will Expand Global Reach
Success in FDA approval for Anaphylm and Libervant expansion could significantly boost revenue and market penetration.Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark
Mar 21Aquestive Therapeutics: Five Foci For 2025
Jan 06The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%
Dec 19Aquestive: Rare Opportunity With Dual Platform Strategy
Nov 05Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Sep 07Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aug 20Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Shareholder Returns
| AQST | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.3% | -1.3% | 1.7% |
| 1Y | 40.8% | -7.5% | 14.5% |
Return vs Industry: AQST exceeded the US Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: AQST exceeded the US Market which returned 14.5% over the past year.
Price Volatility
| AQST volatility | |
|---|---|
| AQST Average Weekly Movement | 12.4% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AQST's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AQST's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 142 | Dan Barber | www.aquestive.com |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
Aquestive Therapeutics, Inc. Fundamentals Summary
| AQST fundamental statistics | |
|---|---|
| Market cap | US$848.03m |
| Earnings (TTM) | -US$65.04m |
| Revenue (TTM) | US$44.13m |
Is AQST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AQST income statement (TTM) | |
|---|---|
| Revenue | US$44.13m |
| Cost of Revenue | US$17.17m |
| Gross Profit | US$26.96m |
| Other Expenses | US$92.00m |
| Earnings | -US$65.04m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 61.09% |
| Net Profit Margin | -147.38% |
| Debt/Equity Ratio | -48.1% |
How did AQST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 20:02 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aquestive Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Gary Nachman | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |